HESI Pharmacology IV Exam

Correct answer B: Decreased muscle spasms

Explanation of the correct answer:

B. Decreased muscle spasms

Baclofen (Lioresal) is a muscle relaxant and antispasmodic medication that is commonly prescribed to patients with multiple sclerosis (MS) to manage spasticity and muscle spasms. The primary therapeutic effect of baclofen is to decrease muscle spasms by acting on the central nervous system (CNS), specifically the GABA receptors in the spinal cord. This leads to a reduction in the frequency and severity of involuntary muscle contractions associated with spasticity, which is a common symptom of MS. Baclofen helps to improve mobility and comfort in clients with MS who experience these muscle spasms.

Why the other options are incorrect:

A. Increased muscle tone

Baclofen does not increase muscle tone. In fact, it is used to decrease muscle tone by reducing spasticity and muscle spasms. It works by inhibiting excessive neuronal activity that leads to the increased muscle tone seen in conditions like MS.

C. Increased range of motion

While baclofen may help improve mobility by decreasing muscle spasms and stiffness, increased range of motion is not the primary therapeutic effect of the medication. Baclofen primarily focuses on reducing spasms rather than directly improving the flexibility or movement of joints.

D. Decreased local pain and tenderness

Baclofen is not primarily used for pain management. It is an antispasmodic, not an analgesic, so its effect on pain and tenderness is secondary to its main function of reducing muscle spasms. Pain relief may occur as a secondary benefit if muscle spasms are contributing to discomfort, but this is not the primary goal of treatment with baclofen.

Summary:

Baclofen is primarily used to decrease muscle spasms in clients with multiple sclerosis by acting on the CNS to reduce spasticity. It is not intended to increase muscle tone, directly increase range of motion, or primarily reduce pain.

Correct answer C: Serum amylase

Explanation of the correct answer:

C. Serum amylase

Didanosine (Videx), an antiretroviral medication used in the treatment of HIV/AIDS, is associated with an increased risk of pancreatitis. Elevated serum amylase is a key indicator of pancreatic dysfunction, and if this level becomes significantly elevated, the healthcare provider may consider discontinuing the medication. Pancreatitis is a serious and potentially life-threatening side effect of didanosine, and monitoring serum amylase levels is essential to detect this condition early.

Why the other options are incorrect:

A. Serum protein

While serum protein levels can provide useful information about the overall nutritional status and liver function, elevated serum protein is not a typical cause for discontinuing didanosine therapy. Serum protein is not directly related to the risk of pancreatitis caused by didanosine.

B. Blood glucose

Blood glucose levels can be affected by many factors, including certain medications, but didanosine does not typically cause significant hyperglycemia or hypoglycemia to the extent that it would require discontinuation. Blood glucose monitoring is important in some situations, but it is not the most relevant factor for stopping didanosine.

D. Serum creatinine

Serum creatinine is primarily used to assess renal function, and although didanosine can have renal side effects, it is not as strongly associated with renal failure as it is with pancreatitis. An elevated serum creatinine would require investigation, but it is the serum amylase level that is more specifically linked to the risk of pancreatitis with didanosine use.

Summary:

If serum amylase is significantly elevated in a client taking didanosine (Videx), it could indicate pancreatitis, a serious side effect of the medication. In this case, the healthcare provider may decide to discontinue the medication. Monitoring serum amylase is crucial in detecting this potential complication.

Correct Answer A: Tinnitus

Explanation of the Correct Answer:

A. Tinnitus is correct because it is a classic early sign of salicylate (salicylic acid) toxicity. Salicylic acid, when absorbed systemically in excessive amounts—either through extensive topical use or ingestion—can lead to salicylism. Symptoms of salicylism include ringing in the ears (tinnitus), dizziness, headache, nausea, and confusion. Tinnitus often presents before more serious symptoms and serves as an important clinical indicator of potential toxicity.

Why the other options are incorrect:

B. Diarrhea is incorrect because it is not a hallmark symptom of salicylate toxicity. While gastrointestinal upset may occur with systemic salicylate ingestion, diarrhea specifically is not a reliable or common indicator of toxicity.

C. Constipation is incorrect because salicylate toxicity does not typically manifest with constipation. In fact, systemic absorption of salicylates more commonly causes nausea and vomiting rather than slowed bowel function.

D. Decreased respirations is incorrect because salicylate toxicity generally causes increased respiratory rate (hyperventilation) due to stimulation of the respiratory center in the brain, leading to respiratory alkalosis in the early stages. Decreased respirations may occur later with severe toxicity and respiratory failure, but this is a late and more critical sign, not an early or reliable indicator.

Summary:

The presence of tinnitus is the most reliable early indicator of systemic toxicity from salicylic acid. Other options like diarrhea, constipation, and decreased respirations are not characteristic early signs and may indicate other conditions or late-stage complications. Therefore, the nurse should be particularly vigilant for tinnitus in clients receiving salicylic acid therapy.

Correct Answer D: Suction equipment

Explanation of the Correct Answer:

D. Suction equipment

Acetylcysteine (Mucomyst) is commonly used to break down mucus in the airways, making it easier to clear. This medication is often administered through a nebulizer, especially in clients with chronic obstructive pulmonary disease (COPD), cystic fibrosis, or other respiratory conditions where thick mucus is present. One of the side effects of acetylcysteine is that it can cause excessive mucus production. The client may have difficulty clearing the mucus from the airways, leading to increased secretions. Therefore, it is essential to have suction equipment available in case the client has difficulty clearing the mucus and needs assistance to maintain a clear airway. Suctioning can help remove excess secretions, preventing aspiration or respiratory distress.

Why the Other Options Are Incorrect:

A. Ambu bag

An Ambu bag is a device used for manual resuscitation, often in cases of respiratory failure. While it is important to have emergency resuscitation equipment available in some clinical settings, it is not specifically needed for a client receiving acetylcysteine via nebulizer unless there is a significant respiratory emergency. In this scenario, the main concern is the increased mucus production that might require suctioning, not immediate ventilation or resuscitation.

B. Intubation tray

An intubation tray contains the necessary equipment to insert a breathing tube (endotracheal tube) in a client who has lost the ability to maintain their airway. While intubation may be necessary in some cases of respiratory failure, it is not a routine requirement when administering acetylcysteine, unless the client fails to clear secretions or develops significant respiratory distress. The primary concern with acetylcysteine administration is the need for suctioning to clear excess mucus, not intubation.

C. Nasogastric tube

A nasogastric tube is used for feeding or drainage in the stomach. While it may be used in some patients with certain conditions (such as gastrointestinal issues), it is not directly relevant to the administration of acetylcysteine, especially when given by nebulizer for respiratory purposes. A nasogastric tube would not help with clearing mucus from the airway, which is the primary concern after giving acetylcysteine.

Summary:

When administering acetylcysteine (Mucomyst) via nebulizer, the nurse should have suction equipment readily available. This medication helps break down mucus, which can lead to increased mucus production that may need to be suctioned to prevent airway obstruction. Ambu bags, intubation trays, and nasogastric tubes are not necessary in this scenario unless there is a significant emergency.

Correct answer A: Serum glucose.

Explanation of the correct answer:

A. Serum glucose

Methylprednisolone (Solu-Medrol) is a corticosteroid, and corticosteroids can increase serum glucose levels by promoting gluconeogenesis (the production of glucose from non-carbohydrate sources) and reducing the sensitivity of cells to insulin. This effect can lead to hyperglycemia, especially in clients with diabetes or those at risk for developing diabetes. Therefore, the nurse should monitor serum glucose levels regularly in clients receiving methylprednisolone.

Why the other options are incorrect:

B. Serum calcium

Corticosteroids like methylprednisolone can actually decrease serum calcium levels by inhibiting calcium absorption in the intestines and increasing calcium excretion in the kidneys. Therefore, an increase in serum calcium is not expected with methylprednisolone therapy.

C. Red blood cells

Corticosteroids can stimulate the production of red blood cells to some extent, but the effect is not significant enough to cause a noticeable increase in red blood cell count. Red blood cell count changes are not a primary concern with methylprednisolone use.

D. Serum potassium

Corticosteroids can cause a decrease in serum potassium levels (hypokalemia) due to their effect on sodium retention and potassium excretion in the kidneys. However, serum potassium levels are typically decreased rather than increased with methylprednisolone therapy.

Summary:

The most significant laboratory value that is likely to increase with methylprednisolone use is serum glucose, as corticosteroids can raise blood glucose levels by influencing insulin resistance and glucose production. Therefore, option A is the correct choice.

Correct Answer B: Refrigerate the insulin

Explanation of the Correct Answer:

B. Refrigerate the insulin is correct because unopened vials of insulin should be stored in the refrigerator at a temperature between 36°F and 46°F (2°C to 8°C). This ensures the insulin remains stable and maintains its potency until it is ready for use. Insulin should never be frozen, as freezing can destroy its effectiveness. Once opened, the insulin can be kept at room temperature for up to 28 days.

Why the other options are incorrect:

A. Freeze the insulin is incorrect because insulin should never be frozen. Freezing insulin can cause it to lose its effectiveness and potentially damage the insulin molecules. If insulin has been frozen, it should not be used, and a new vial should be obtained.

C. Store the insulin in a dark, dry place is incorrect because while insulin should be kept out of direct sunlight and heat, refrigeration is necessary for unopened vials. Storing it in a dark, dry place at room temperature is suitable for opened insulin, but it does not apply to unopened vials, which need to be refrigerated to preserve their integrity.

D. Keep the insulin at room temperature is incorrect for unopened vials. Unopened insulin should be stored in the refrigerator. However, once the vial has been opened, it can be kept at room temperature for up to 28 days to make it more comfortable to inject.

Summary:

Unopened insulin vials should be refrigerated to maintain their stability and potency until they are ready to be used. Freezing insulin, storing it in a dark, dry place, or keeping it at room temperature before opening are not appropriate for the preservation of unopened insulin.

Correct answer A: High dose methylprednisolone intravenously.

Explanation of the correct answer:

A. High dose methylprednisolone intravenously.

In the case of multiple sclerosis (MS), exacerbations (episodes where symptoms worsen, such as profound weakness, blurry vision, and shooting pains) are often treated with high-dose intravenous corticosteroids, such as methylprednisolone. The purpose of these steroids is to reduce inflammation and suppress immune system activity that may be contributing to the neurological damage in MS. Methylprednisolone is commonly used to treat acute MS flare-ups and can help to shorten the duration of symptoms during an exacerbation.

Why the other options are incorrect:

B. Baclofen three times a day.

Baclofen is a muscle relaxant used to help with spasticity (muscle stiffness or tightness) associated with multiple sclerosis, but it is not used to treat acute exacerbations. It does not address the underlying inflammation or acute symptoms like weakness and blurry vision in a flare-up.

C. Broad spectrum antibiotic coverage orally.

Antibiotics are used to treat infections, not to address the neurological symptoms or inflammatory exacerbations of multiple sclerosis. The symptoms described (weakness, blurry vision, and shooting pains) are not consistent with an infection, so antibiotics would not be appropriate.

D. Immunomodulatory drug therapy periodically.

Immunomodulatory drugs (e.g., interferons, glatiramer acetate) are typically used for long-term disease-modifying therapy to reduce the frequency of exacerbations in relapsing-remitting MS. However, during an acute flare-up, high-dose corticosteroids are usually the first-line treatment, not immunomodulatory therapy.

Summary:

For a client experiencing an acute exacerbation of multiple sclerosis with symptoms like profound weakness, blurry vision, and shooting pains, the best course of treatment is high-dose methylprednisolone intravenously to reduce inflammation and manage acute symptoms.

Correct answer B: The white blood cell counts and platelet counts

Explanation of the correct answer:

B. The white blood cell counts and platelet counts

Etanercept (Enbrel) is a tumor necrosis factor (TNF) inhibitor used in the treatment of rheumatoid arthritis and other autoimmune disorders. While effective in reducing inflammation and slowing disease progression, etanercept suppresses the immune system, making the client more susceptible to infections and hematologic abnormalities, including leukopenia (low white blood cells) and thrombocytopenia (low platelets).

It is critical for the nurse to monitor complete blood counts (CBC) regularly during therapy. A decrease in white blood cells can increase the risk of serious infections, while a drop in platelets can increase the risk of bleeding. These lab values provide an early warning for potentially severe adverse effects and guide decisions about continuing or adjusting the medication.

Why the other options are incorrect:

A. The injection site for itching and edema

While mild injection site reactions such as redness, itching, or swelling are common and expected with subcutaneous administration of etanercept, they are not the most critical concern. These reactions are usually self-limiting and manageable with symptomatic care.

C. Whether the client is experiencing fatigue and joint pain

Fatigue and joint pain are symptoms of rheumatoid arthritis, not necessarily side effects of etanercept. While it's useful to monitor the client’s clinical response to treatment, these symptoms are not as urgent or serious as hematologic complications.

D. A metallic taste in the mouth, with a loss of appetite

These symptoms are not typical or significant side effects of etanercept. They are more commonly associated with medications like metronidazole or chemotherapy drugs, not TNF inhibitors.

Summary:

Monitoring white blood cell and platelet counts is most important when administering etanercept, due to the risk of immunosuppression and hematologic abnormalities. While local injection reactions and joint symptoms may occur, they are less critical than potentially life-threatening changes in blood counts.

Correct Answer A: Pancreatitis

Explanation of the Correct Answer:

A. Pancreatitis is correct because asparaginase (Elspar), an antineoplastic agent, is known to have pancreatic toxicity as a potential side effect. The medication can cause acute pancreatitis, which is an inflammation of the pancreas that may result in abdominal pain, nausea, vomiting, and other related symptoms. If a client has a history of pancreatitis, the nurse must consult with the registered nurse and likely the healthcare provider before proceeding with asparaginase treatment. Monitoring for signs of pancreatitis and performing baseline and ongoing assessments of the client's pancreatic function would be essential to prevent complications.

Why the other options are incorrect:

B. Diabetes mellitus is incorrect because although asparaginase may affect blood glucose levels by causing hyperglycemia, it is not a contraindication for administration in a client with diabetes mellitus. Clients with diabetes receiving asparaginase can be managed with adjustments to their insulin regimen or oral hypoglycemic agents. The key consideration would be monitoring the client’s blood glucose levels and adjusting treatment accordingly.

C. Myocardial infarction is incorrect because there is no direct contraindication or significant risk for administering asparaginase to clients with a history of myocardial infarction. While chemotherapy agents can affect the cardiovascular system, asparaginase is not specifically associated with cardiac complications like myocardial infarction, making this history less concerning for this medication.

D. Chronic obstructive pulmonary disease (COPD) is incorrect because COPD is not a contraindication for asparaginase administration. Although the medication may affect general organ function, COPD does not specifically interact with asparaginase in a way that would prevent its use. The focus would be on monitoring for respiratory effects, but it is not an absolute contraindication.

Summary:

The nurse should consult with the registered nurse before administering asparaginase if the client has a history of pancreatitis, as the medication is associated with pancreatic toxicity and can lead to acute pancreatitis. Clients with diabetes mellitus, myocardial infarction, or chronic obstructive pulmonary disease (COPD) can still receive asparaginase, but adjustments or additional monitoring might be necessary for diabetes mellitus to manage hyperglycemia.